Effect of tempe and vitamin C rich fruit supplementation during pregnancy on iron status and pregnancy outcomes

Submission date	Recruitment status	Prospectively registered
06/09/2007	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
08/04/2008	Completed	Results
Last Edited	Condition category	Individual participant data
08/04/2008	Pregnancy and Childbirth	[] Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mrs Maria Wijaya-Erhardt

Contact details

Seameo-Tropmed RCCN-UI Jl. Salemba Raya 6 Jakarta Indonesia 10430 +62 21 3914017 mwijaya@seameo-rccn.org

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Study objectives

Does food-based intervention using tempe and vitamin C rich fruit during pregnancy improve the iron status?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethical Committee for Studies on Human Subjects, Faculty of Medicine, University of Indonesia. Date of approval: 19/02/2007 (ref: 49/PTO2.FK/ETIK/2007)

Study design

Randomised controlled single-centre trial (unit of randomisation: village).

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Prevention

Participant information sheet

Health condition(s) or problem(s) studied

Anaemia during pregnancy

Interventions

The participating villages will be randomly allocated to the following two groups:

Supplementary group will receive supplementary food, 400 mg albendazole, and health and nutrition

education. The average weekly supplementary food consist of: 600 g tempe (fermented soybean), 30 g red meat/dried anchovy/chicken liver, 45 g soy sauce, 350 g guava, 300 g papaya and 100 g orange. Supplementary food will be given daily at 12-20 week of gestation until delivery at home.

Control group will receive 400 mg albendazole only.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Tempe and albendazole

Primary outcome measure

Maternal iron status at gestation 12-20 week:

- 1. Haemoglobin
- 2. Ferritin
- 3. Soluble transferrin receptors

Secondary outcome measures

- 1. Infectious status at gestation 12-20 weeks and 32-36 weeks:
- 1.1. C-reactive protein
- 1.2. A-1 acid glycoprotein
- 2. Helminth infestation (hookworms, A.lumbricoides, T.trichiura) measured quantitatively (eggs per gram) at gestation 12-20 weeks and 32-36 weeks
- 3. Gestational age calculated from date of last menstruation and palpation
- 4. Weight gain of pregnant women and birth weight of infant will be measured with electronic weighing scale
- 5. Length of infant will be measured with length board
- 6. Complication deliveries/fetal loss will be measured with verbal autopsy interviews, less than 3 days after delivery

Overall study start date

01/11/2007

Completion date

01/11/2008

Eligibility

Key inclusion criteria

- 1. Pregnant women, gestation 12-20 weeks
- 2. Age 15-49 years
- 3. No existing severe maternal illness

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

250

Key exclusion criteria

- 1. Suffer from chronic disease
- 2. In medication/antibiotic treatment
- 3. Do not sign inform consent

Date of first enrolment

01/11/2007

Date of final enrolment

01/11/2008

Locations

Countries of recruitment

Indonesia

Study participating centre Seameo-Tropmed RCCN-UI

Jakarta Indonesia 10430

Sponsor information

Organisation

Nestle Foundation (Switzerland)

Sponsor details

4, Place de la Gare PO BOX 581 Lausanne Switzerland 1001 +41 21 320 33 51 nf@nestlefoundation.org

Sponsor type

Industry

Website

http://www.nestlefoundation.org

ROR

https://ror.org/021k07d19

Funder(s)

Funder type Industry

Funder Name

Nestle Foundation (Switzerland)

Results and Publications

Publication and dissemination planNot provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration